These include long-term secondary prevention with dual antiplatelet therapy, the lipid-lowering drugs proprotein convertase subtilisin/kexin type 9 inhibitors and inclisiran, and adding a glucagon-like peptide-1 receptor agonist or sodium-glucose cotransporter 2 inhibitor for patients with diabetes mellitus with established atherosclerotic cardiovascular disease [18]. Here, PCSK9 is linked to diabetes mellitus.